{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["anbenitamab","HB1801"]],"indication":"early or locally advanced HER2-positive breast cancer","name":"Neo-Healer","nct_id":"NCT06747338","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neo-healer-nct06747338. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Neo-Healer","arms":[{"description":"KN026 HB1801 Carboplatin","label":"KN026 plus HB1801 ± Carboplatin","type":"EXPERIMENTAL"},{"description":"Pertuzumab Trastuzumab Docetaxel Carboplatin","label":"Pertuzumab and trastuzumab plus docetaxel ± Carboplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12-16","type":"ESTIMATED"},"conditions":["Early or Locally Advanced HER2-positive Breast Cancer"],"enrollment":{"count":520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"KN026","otherNames":[],"type":"DRUG"},{"name":"HB1801","otherNames":[],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-07","lead_sponsor":"Shanghai JMT-Bio Inc.","official_title":"A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"tpCR (BIRC, AJCC 8th)","timeFrame":"Through study completion, an average of 1 year"}],"references":[{"citation":"Li J, Liu T, Yu KD, Yang H, Huang Z, Zeng Y, Ji P, Hou X, Liu C, Zhang Y, Li N, Ouyang Z, Wu X, Bai X, Guo Y, Han G, Cui S, Zhu Z, Zhang Y, Hu X, Ma X, Fu P, Zhu J, Dong Y, Wu T, Jia H, Xu F, Ren Y, Nie J, Bing D, Mu Q, Sun T, Luo J, Song Z, Kong X, Zhang H, Wu Z, Wang Z, Song D, Jia H, Tao W, Fan P, Yao F, Ru C, Lai G, Zhou X, Li T, Deng C, Jiang X, Wang X, Wang J, Xiong D, Zhang S, Yang H, Yao Y, Yin G, Yao G, Zhou L, Wang S, Yu Z, Yu Y, Lv Y, Qian H, Li H, Guo W, Huang W, Xiang S, Zou K, He H, Fan L, Shao ZM; BCTOP study group. Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 3:e263329. doi: 10.1001/jamaoncol.2026.3329. Online ahead of print.","pmid":"42690668","type":"DERIVED"}],"start_date":{"date":"2024-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06747338"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neo-healer-nct06747338"}